Overview

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of LY2189265 in comparison to Insulin Glargine, both in combination with Insulin Lispro (plus or minus Metformin), in participants with Type 2 Diabetes treated with 1 or 2 injections of insulin.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide
Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc